Search Results - WEISENBACH, Jill

  • Showing 1 - 10 results of 10
Refine Results
  1. 1
    A Dose-Escalation Study of Recombinant Human Interleukin-18 Using Two Different Schedules of Administration in Patients with Cancer

    A Dose-Escalation Study of Recombinant Human Interleukin-18 Using Two Different Schedules of Administration in Patients with Cancer by ROBERTSON, Michael J, KIRKWOOD, John M, LOGAN, Theodore F, KOCH, Kevin M, KATHMAN, Steven, KIRBY, Lyndon C, BELL, William N, THURMOND, Linda M, WEISENBACH, Jill, DAR, Mohammed M

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Clinical and Biological Effects of Recombinant Human Interleukin-18 Administered by Intravenous Infusion to Patients with Advanced Cancer

    Clinical and Biological Effects of Recombinant Human Interleukin-18 Administered by Intravenous Infusion to Patients with Advanced Cancer by ROBERTSON, Michael J, MIER, James W, JEWELL, Roxanne C, BELL, William N, THURMOND, Linda M, WEISENBACH, Jill, ROBERTS, Suzanne, DAR, Mohammed M, LOGAN, Theodore, ATKINS, Michael, KOON, Henry, KOCH, Kevin M, KATHMAN, Steven, PANDITE, Lini N, OEI, Coreen, KIRBY, Lyndon C

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    P62SQSTM1 Affects Interacting Substrates MDM2, MDMX and Casein Kinase 1alpha to Yield Protection of Beta-Catenin Along with p53 Silencing for Refractory AML

    P62SQSTM1 Affects Interacting Substrates MDM2, MDMX and Casein Kinase 1alpha to Yield Protection of Beta-Catenin Along with p53 Silencing for Refractory AML by Layer, Justin, Rangaraju, Sravanti, Pasupuleti, Santhosh, Cripe, Larry D., Sayar, Hamid, Sargent, Katie J, Weisenbach, Jill, Salman, Huda S., Roodman, G. David, Mayo, Linsey, Kapur, Reuben, Dave', Utpal P, Boswell, H. Scott

    Published in Blood
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Final Results of Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib in Acute Myeloid Leukemia with FLT3-ITD Mutation or Poor-Risk Cytogenetics

    Final Results of Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib in Acute Myeloid Leukemia with FLT3-ITD Mutation or Poor-Risk Cytogenetics by Saliba, Antoine N, Boswell, H. Scott, Cripe, Larry D, Abu Zaid, Mohammad Issam, Weisenbach, Jill, Sayar, Hamid

    Published in Blood
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    Phase I Study of Recombinant Human Interleukin-18 (IL-18) in Combination with Ofatumumab after Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) for Lymphoma

    Phase I Study of Recombinant Human Interleukin-18 (IL-18) in Combination with Ofatumumab after Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) for Lymphoma by Robertson, Michael J., Ni, Lijun, Weisenbach, Jill, Pelloso, David, Prasad, Nagendra K.

    Published in Blood
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib in Acute Myeloid Leukemia with FLT3-ITD Mutation or Monosomy 5, 7, or Complex Cytogenetics

    Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib in Acute Myeloid Leukemia with FLT3-ITD Mutation or Monosomy 5, 7, or Complex Cytogenetics by Abu Zaid, Mohammad, Boswell, H. Scott, Cripe, Larry D., Liu, Yan, Weisenbach, Jill, Sayar, Hamid

    Published in Blood
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  7. 7
    Consecutive epigenetically-active agent combinations act in ID1-RUNX3-TET2 and HOXA pathways for Flt3ITD+ve AML

    Consecutive epigenetically-active agent combinations act in ID1-RUNX3-TET2 and HOXA pathways for Flt3ITD+ve AML by Sayar, Hamid, Liu, Yan, Gao, Rui, Zaid, Mohammad Abu, Cripe, Larry D, Weisenbach, Jill, Sargent, Katie J, Nassiri, Mehdi, Li, Lang, Konig, Heiko, Suvannasankha, Attaya, Pan, Feng, Shanmugam, Rajasubramaniam, Goswami, Chirayu, Kapur, Reuben, Xu, Mingjiang, Boswell, H Scott

    Published in Oncotarget
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  8. 8
    Rituximab, Bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis

    Rituximab, Bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis by Ganjoo, Kristen N., An, Caroline S., Robertson, Michael J., Gordon, Leo I., Sen, Joy A., Weisenbach, Jill, Li, Shuli, Weller, Edie A., Orazi, Attilio, Horning, Sandra J.

    Published in Leukemia & lymphoma
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  9. 9
    Phase I Trial Evaluating the Safety and Biological Activity of Iboctadekin (rhIL-18) in Combination with Rituximab in Patients with CD20+ B Cell Non-Hodgkin's Lymphoma

    Phase I Trial Evaluating the Safety and Biological Activity of Iboctadekin (rhIL-18) in Combination with Rituximab in Patients with CD20+ B Cell Non-Hodgkin's Lymphoma by Robertson, Michael J., Bauman, John, Gardner, Olivia, Jonak, Zdenka, Struemper, Herbert, Germaschewski, Fiona, Koch, Kevin M., Murray, Sharon, Weisenbach, Jill, Toso, John

    Published in Blood
    Get full text
    Article
    Save to List
    Saved in:
  10. 10
    Cyclic Administration of Combination of Sorafenib and Vorinostat In Poor-Risk AML: A Pharmacodynamically-Oriented Extended Phase I Trial

    Cyclic Administration of Combination of Sorafenib and Vorinostat In Poor-Risk AML: A Pharmacodynamically-Oriented Extended Phase I Trial by Sayar, Hamid, Cripe, Larry, Cangany, Mary, Weisenbach, Jill, Sargent, Katie J., Goswami, Chirayu, Li, Lang, Wilson-Weekes, Annique, Shanmugam, Rajasubramaniam, Boswell, H. Scott

    Published in Blood
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: